Fosrenol (lanthanum carbonate) / Takeda 
Welcome,         Profile    Billing    Logout  
 17 Diseases   9 Trials   9 Trials   424 News 


123456»
  • ||||||||||  Fosrenol (lanthanum carbonate) / Takeda
    Preclinical, Journal:  Effect of cerium oxide on iron metabolism in mice. (Pubmed Central) -  Nov 25, 2024   
    Another group was administrated lanthanum carbonate, which is currently used as a phosphorus adsorbent...These results indicate that nanoceria administration can affect iron metabolism in mice. Although the detailed mechanism remains unknown, caution is warranted when considering biological utilization in the future.
  • ||||||||||  Fosrenol (lanthanum carbonate) / Takeda
    Journal:  LANTHANUM DEPOSITS AS A RARE DIFFERENTIAL DIAGNOSIS OF VILLOUS ATROPHY (Pubmed Central) -  Nov 14, 2024   
    In order to reduce his serum phosphate levels, he was treated with a high dose of lanthanum carbonate, one of the most effective and safe non-calcium-based phosphate binders...This case illustrates a rare differential diagnosis of villous atrophy typical for end-stage renal disease patients, that can be categorized as an iatrogenic and infiltrative aetiology for villous atrophy. Since the long-term consequences of lanthanum deposition in tissue are unknown, this case also emphasizes the need for a multidisciplinary approach for treating dialysis patients, in order to understand which phosphate binder was provided.
  • ||||||||||  Auryxia (ferric citrate) / Akebia Therap, Fosrenol (lanthanum carbonate) / Takeda, Ibsrela (tenapanor) / Ardelyx
    Current and Future State of Hyperphosphatemia Management () -  Oct 12, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_5024;    
    With the eventual availability of a generic ferric citrate product, nephrologists project that their use of calcium-based binders and sevelamer will decline, while their use of ferric citrate products and tenapanor will expand...Tenapanor's user base among nephrologists (61%) has continued to increase month-over-month since its launch, as physicians have been prescribing the agent to a higher volume of their dialysis patients.Among the pipeline agents in development for hyperphosphatemia, oxylanthanum carbonate (OLC) has advanced to late-stage clinical development, with most nephrologists expressing interest in the product due to its bioequivalence to lanthanum carbonate, reduced pill burden, and smaller pill size...Conclusion. Pending adequate medication access, nephrologists expect to have more treatment options available to them to help reduce the proportion of patients who do not reach their target phosphorus range, along with the potential added benefit of improving quality of life for their hyperphosphatemia patients..
  • ||||||||||  Fosrenol (lanthanum carbonate) / Takeda, Ibsrela (tenapanor) / Ardelyx
    Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in Rats (Exhibit Hall, Convention Center) -  Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_3729;    
    Combination OLC+tenapanor demonstrates more pronounced P reduction than either agent used alone. The magnitude of P lowering suggests effect of OLC+tenapanor is synergistic rather than additive.
  • ||||||||||  Fosrenol (lanthanum carbonate) / Takeda
    Journal:  Lanthanum Gastropathy in Gastrectomy Specimen: A Case Report. (Pubmed Central) -  Aug 21, 2024   
    Lanthanum carbonate (LC) is a phosphate binder used in end-stage renal disease (ESRD) with few adverse effects due to poor systemic absorption...Years later, the excised portion had similar findings. This case allows for evaluation of LC gastropathy in a resection specimen, providing the opportunity to showcase its unique pathology features.
  • ||||||||||  Fosrenol (lanthanum carbonate) / Takeda
    A Case of Mistaken Identity: Lanthanum Carbonate Tablet Mimicking Esophageal Button Battery (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_2928;    
    Being aware of these would help avoid unnecessary diagnostic testing in these patients. Figure: A - Fluoroscopy demonstrating densely radiopaque discoid esophageal foreign body from lateral view B - Chest X-ray redemonstrating densely radiopaque discoid esophageal foreign body C - Large tablet resembling lanthanum carbonate as seen on endoscopy after being pushed down into the stomach
  • ||||||||||  Fosrenol (lanthanum carbonate) / Takeda
    Journal:  Lanthanum deposition of the gastric mucosa in a dialysis patient. (Pubmed Central) -  Aug 1, 2024   
    He was taking lanthanum carbonate (LaC) for hyperphosphatemia...The gastric endoscopic findings of La deposition reflect the infiltrated histiocytes and not the LC deposition itself. Our case highlights the importance of recognizing the rare but characteristic imaging findings of gastrointestinal La deposition in hemodialysis patients who are taking LaC.
  • ||||||||||  Fosrenol (lanthanum carbonate) / Takeda
    LANTHANUM DEPOSITS AS A RARE DIFFERENTIAL DIAGNOSIS OF VILLOUS ATROPHY (Science Lounge) -  Jul 18, 2024 - Abstract #UEGW2024UEGW_861;    
    In order to reduce his serum phosphate levels, he was treated with high dose of Lanthanum Carbonate, one of the most effective and safe noncalcium-based phosphate binders.During weight loss investigation, he underwent gastroscopy that demonstrated duodenal denudated mucosa with villous blunting (1)...Von Kossa staining, that was performed, emphasized the depositions of the foreign material that has been identified as Lanthanum (3). Consequently, the treatment with Lanthanum has been stopped and replaced by another phosphate binder.This case illustrates a rare differential diagnosis of villous atrophy typical for end-stage renal disease patients, that can be categorized as iatrogenic and infiltrative etiology for villous atrophy.Since the long-term consequences of lanthanum deposition in tissue are unknown, this case also emphasizes the need for multidisciplinary approach for treating dialysis patients, in order to understand which phosphate binder has been given.Points to discuss:D.D of villous atrophySeronegative celiac
  • ||||||||||  Fosrenol (lanthanum carbonate) / Takeda
    Trial completion:  A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis (clinicaltrials.gov) -  Jun 14, 2024   
    P2,  N=86, Completed, 
    Consequently, the treatment with Lanthanum has been stopped and replaced by another phosphate binder.This case illustrates a rare differential diagnosis of villous atrophy typical for end-stage renal disease patients, that can be categorized as iatrogenic and infiltrative etiology for villous atrophy.Since the long-term consequences of lanthanum deposition in tissue are unknown, this case also emphasizes the need for multidisciplinary approach for treating dialysis patients, in order to understand which phosphate binder has been given.Points to discuss:D.D of villous atrophySeronegative celiac Active, not recruiting --> Completed
  • ||||||||||  Fosrenol (lanthanum carbonate) / Takeda
    Journal:  Safety and efficacy of a feed additive consisting of lanthanum carbonate octahydrate for dogs (Porus GmbH). (Pubmed Central) -  Apr 11, 2024   
    The additive is not irritant to skin or eyes, is not a skin sensitiser and exposure by inhalation is considered to be unlikely. The Panel also concluded that lanthanum carbonate octahydrate is efficacious in the reduction of phosphorus bioavailability in adult dogs at the minimum inclusion level of 1500 mg/kg complete feed.
  • ||||||||||  Fosrenol (lanthanum carbonate) / Takeda
    Journal:  Structural design of La2(CO3)3 loaded magnetic biochar for selective removal of phosphorus from wastewater. (Pubmed Central) -  Mar 13, 2024   
    These findings enhance the understanding of LMB's application in efficient wastewater phosphorus removal. Holding significant promise in wastewater remediation, the LMB acts as an effective adsorbent, contributing substantially to the prevention and control of various types of phosphorus pollutants, thereby mitigating wastewater eutrophication.
  • ||||||||||  Ibsrela (tenapanor) / Ardelyx, Kyowa Kirin, Knight Therap
    Journal:  Tenapanor (Xphozah) for hyperphosphatemia in chronic kidney disease. (Pubmed Central) -  Mar 2, 2024   
    Holding significant promise in wastewater remediation, the LMB acts as an effective adsorbent, contributing substantially to the prevention and control of various types of phosphorus pollutants, thereby mitigating wastewater eutrophication. No abstract available
  • ||||||||||  Fosrenol (lanthanum carbonate) / Takeda
    Journal:  Optimization of the adsorption performance of herbal residues as lanthanide ion-modified carriers for phosphate by fly ash and its application. (Pubmed Central) -  Dec 5, 2023   
    In this paper, a composite adsorbent (LC-MM) was synthesized by hydrothermal treatment of waste traditional Chinese medical materials (MMs) with load of lanthanum carbonate and co-heating treatment with coal fly ash (CFA), which was applied to remove phosphate from water...The ligand exchange between phosphate and carbonate, the internal spherical complexation formed by lanthanum ion and phosphate, and surface chemical precipitation attachment are the main reasons why the adsorption capacity of LC-MM approached or even surpassed that of conventional lanthanum-modified adsorbents. In conclusions, this work proposed an effective method for the modification of plant materials.
  • ||||||||||  TPOXX (tecovirimat) / SIGA Technologies
    Trial completion:  Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders (clinicaltrials.gov) -  Jul 20, 2023   
    P4,  N=44, Completed, 
    A randomized trial that compares gastrointestinal tolerability across binders would be warranted to demonstrate acceptability and adherence in the target population. Active, not recruiting --> Completed
  • ||||||||||  Fosrenol (lanthanum carbonate) / Takeda
    Retrospective data, Review, Journal:  Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients. (Pubmed Central) -  Jun 9, 2023   
    This study was designed to examine the relative safety and efficacy of sevelamer in the treatment of chronic kidney disease (CKD) patients in comparison to placebo, calcium carbonate (CC), or lanthanum carbonate (LC)...No significant differences in gastrointestinal adverse events (GAEs) incidence were observed. These data suggest that sevelamer may represent a beneficial means of protecting CKD patients against death and vessel calcification when used to treat hyperphosphatemia, while we found no clinically important benefits in decreasing gastrointestinal adverse effects.
  • ||||||||||  Auryxia (ferric citrate) / Japan Tobacco, Akebia Therap, Fosrenol (lanthanum carbonate) / Takeda, Renazorb (lanthanum dioxycarbonate) / Unicycive
    MEDICATION VOLUME COMPARISON TO BIND PHOSPHATE (Focussed Oral Room 8) -  May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1323;    
    With a low medication volume and high phosphate binding capacity, lanthanum dioxycarbonate, a novel investigational nanotechnology product, can be a welcoming choice for patients to manage their hyperphosphatemia. The drug's decreased pill size (making it easy to swallow) and its tolerability have the potential to increase medication adherence and improve phosphate control.
  • ||||||||||  Auryxia (ferric citrate) / Japan Tobacco, Akebia Therap, Fosrenol (lanthanum carbonate) / Takeda, Velphoro (sucroferric oxyhydroxide) / Fresenius Kabi, Kissei
    Review, Journal:  The Role of Iron-Based Phosphate Binder in the Treatment of Hyperphosphatemia. (Pubmed Central) -  Apr 23, 2023   
    These have an important role in controlling phosphate levels due to their ability to lower the phosphate while concurrently providing iron sources. This review provides pharmacological profiles of different phosphate binders and their clinical usages, and further elaborates on their place in hyperphosphatemia management.
  • ||||||||||  DAILY MEDICATION VOLUME OF PHOSPHATE BINDER THERAPIES () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_928;    
    Conclusions Due to its low daily dose volume, lanthanum dioxycarbonate, a novel investigational nanotechnology product, may be a welcome choice for patients to manage their hyperphosphatemia. The drug
  • ||||||||||  Fosrenol (lanthanum carbonate) / Takeda, Renazorb (lanthanum dioxycarbonate) / Unicycive
    IN-VIVO PHOSPHATE REDUCTION: LANTHANUM DIOXYCARBONATE VS LANTHANUM CARBONATE TETRAHYDRATE () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_925;    
    Figure 1: Mean Urine Phosphate Excretion/Day View Large Image Figure Viewer Download Hi-res image Download (PPT) Conclusions Similar to LCTH, LDC was effective on day 1 in lowering P levels and maintaining low P levels. These results suggest that per amount of active elemental lanthanum, LDC has similar efficacy as LCTH while having a potentially smaller pill size that is swallowed with water, which may improve patient QoL.
  • ||||||||||  Daily Medication Volume of Phosphate Binder Therapies () -  Oct 15, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_4444;    
    Conclusion Lanthanum dioxycarbonate, a novel investigational nanotechnology product, may be a welcome choice for patients to manage their hyperphosphatemia. Improved size (easily swallowed) and tolerability have the potential to increase medication adherence and phosphate control.
  • ||||||||||  Fosrenol (lanthanum carbonate) / Takeda
    The Associations of Kidney Functional Magnetic Resonance Imaging Biomarkers of Oxygenation and Fibrosis With Inflammatory Biomarkers in Individuals With Advanced CKD (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_2721;    
    Methods We evaluated the association of baseline kidney functional magnetic resonance imaging (fMRI) biomarkers of oxygenation and fibrosis with interleukin-6 (IL-6) and C-reactive protein (CRP) in 127 participants from the COMBINE trial, which was a randomized, 12-month study of nicotinamide and lanthanum carbonate vs. placebo in individuals with CKD stages 3-4...Conclusion In individuals with advanced CKD, higher cortical ADC, suggestive of less cortical fibrosis, was associated with lower inflammation, as assessed by IL-6 and CRP. Kidney fMRI biomarkers did not associate with change in inflammatory biomarkers over time.
  • ||||||||||  Fosrenol (lanthanum carbonate) / Takeda
    Therapeutic Strategies for Reversing the Negative Health Effects of a High Phosphate Diet in Mice (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_2655;    
    Conclusion Though individually existing, clinically used therapies are generally effective at correcting some aspects of systemic phosphate dysbiosis in mice, they generally do not correct negative consequences on bone volume. This suggests that the negative health consequences of dysregulated phosphate homeostasis, even in the context of normal renal function, are multifactorial and cannot be fully alleviated with existing clinically used therapies.